Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free ELYM Stock Alerts

Eliem Therapeutics (ELYM) Competitors

Eliem Therapeutics logo
$9.69 +0.78 (+8.75%)
As of 05/4/2026
Compare

ELYM vs. JBIO, COLL, CMPS, SEPN, and QURE

Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Jade Biosciences (JBIO), Collegium Pharmaceutical (COLL), Compass Pathways (CMPS), Septerna (SEPN), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Eliem Therapeutics compare to Jade Biosciences?

Eliem Therapeutics (NASDAQ:ELYM) and Jade Biosciences (NASDAQ:JBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Comparatively, Jade Biosciences has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A
Jade BiosciencesN/AN/A-$127.41M-$4.61N/A

In the previous week, Jade Biosciences had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Jade Biosciences and 1 mentions for Eliem Therapeutics. Jade Biosciences' average media sentiment score of 0.89 beat Eliem Therapeutics' score of 0.67 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eliem Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jade Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jade Biosciences' return on equity of -46.55% beat Eliem Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
Jade Biosciences N/A -46.55%-42.99%

Jade Biosciences has a consensus price target of $31.17, suggesting a potential upside of 23.38%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Jade Biosciences is more favorable than Eliem Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Jade Biosciences
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.89

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 24.9% of Jade Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Jade Biosciences beats Eliem Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Eliem Therapeutics compare to Collegium Pharmaceutical?

Eliem Therapeutics (NASDAQ:ELYM) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Collegium Pharmaceutical has a consensus price target of $53.40, indicating a potential upside of 51.02%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Eliem Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Collegium Pharmaceutical
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

In the previous week, Eliem Therapeutics and Eliem Therapeutics both had 1 articles in the media. Eliem Therapeutics' average media sentiment score of 0.67 beat Collegium Pharmaceutical's score of -0.21 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eliem Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Collegium Pharmaceutical
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Collegium Pharmaceutical has a net margin of 8.05% compared to Eliem Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 98.65% beat Eliem Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
Collegium Pharmaceutical 8.05%98.65%15.86%

69.8% of Eliem Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Collegium Pharmaceutical has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A
Collegium Pharmaceutical$780.57M1.47$62.87M$1.7120.68

Summary

Collegium Pharmaceutical beats Eliem Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Eliem Therapeutics compare to Compass Pathways?

Eliem Therapeutics (NASDAQ:ELYM) and Compass Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Compass Pathways has a consensus price target of $20.45, indicating a potential upside of 119.47%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Eliem Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Compass Pathways
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Comparatively, Compass Pathways has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500.

In the previous week, Compass Pathways had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 5 mentions for Compass Pathways and 1 mentions for Eliem Therapeutics. Compass Pathways' average media sentiment score of 0.70 beat Eliem Therapeutics' score of 0.67 indicating that Compass Pathways is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eliem Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Compass Pathways
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Eliem Therapeutics' return on equity of -47.03% beat Compass Pathways' return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
Compass Pathways N/A -192.95%-61.31%

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A
Compass PathwaysN/AN/A-$287.86M-$3.09N/A

Summary

Compass Pathways beats Eliem Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Eliem Therapeutics compare to Septerna?

Eliem Therapeutics (NASDAQ:ELYM) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Septerna has a consensus price target of $43.13, indicating a potential upside of 78.72%. Given Septerna's stronger consensus rating and higher possible upside, analysts clearly believe Septerna is more favorable than Eliem Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Septerna
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Comparatively, Septerna has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.

In the previous week, Septerna had 5 more articles in the media than Eliem Therapeutics. MarketBeat recorded 6 mentions for Septerna and 1 mentions for Eliem Therapeutics. Septerna's average media sentiment score of 1.12 beat Eliem Therapeutics' score of 0.67 indicating that Septerna is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eliem Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Septerna
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Eliem Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -106.37%. Septerna's return on equity of -15.85% beat Eliem Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
Septerna -106.37%-15.85%-11.96%

69.8% of Eliem Therapeutics shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eliem Therapeutics has higher earnings, but lower revenue than Septerna. Septerna is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A
Septerna$45.95M23.60-$48.88M-$1.11N/A

Summary

Septerna beats Eliem Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Eliem Therapeutics compare to uniQure?

Eliem Therapeutics (NASDAQ:ELYM) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Eliem Therapeutics has higher earnings, but lower revenue than uniQure. Eliem Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A
uniQure$16.10M82.89-$198.97M-$3.45N/A

Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Comparatively, uniQure has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

uniQure has a consensus price target of $44.50, suggesting a potential upside of 110.30%. Given uniQure's stronger consensus rating and higher probable upside, analysts clearly believe uniQure is more favorable than Eliem Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eliem Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
uniQure
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53

In the previous week, uniQure had 23 more articles in the media than Eliem Therapeutics. MarketBeat recorded 24 mentions for uniQure and 1 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.67 beat uniQure's score of 0.59 indicating that Eliem Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eliem Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
uniQure
6 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Eliem Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,236.00%. Eliem Therapeutics' return on equity of -47.03% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
Eliem TherapeuticsN/A -47.03% -45.97%
uniQure -1,236.00%-174.03%-27.41%

69.8% of Eliem Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 4.7% of Eliem Therapeutics shares are owned by company insiders. Comparatively, 4.8% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

uniQure beats Eliem Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Eliem Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELYM vs. The Competition

Export
MetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$288.30M$886.55M$6.25B$11.77B
Dividend YieldN/A4.84%2.74%5.26%
P/E Ratio-18.280.9624.9123.23
Price / SalesN/A120.65504.5675.49
Price / CashN/A20.0743.3053.90
Price / Book2.487.609.676.69
Net Income-$35.12M-$4.80M$3.55B$332.64M
7 Day Performance2.00%-0.05%1.70%2.01%
1 Month Performance47.71%5.50%5.62%9.19%
1 Year Performance662.99%30.96%34.42%39.59%

Eliem Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELYM
Eliem Therapeutics
N/A$9.69
+8.8%		N/AN/A$288.30MN/AN/A9
JBIO
Jade Biosciences
3.2647 of 5 stars		$22.32
-15.6%		$31.17
+39.6%		N/A$1.10BN/AN/A20
COLL
Collegium Pharmaceutical
2.6681 of 5 stars		$33.76
+2.9%		$53.40
+58.2%		N/A$1.09B$780.57M19.74210
CMPS
Compass Pathways
3.0303 of 5 stars		$8.38
-0.7%		$20.70
+147.0%		N/A$1.08BN/AN/A120
SEPN
Septerna
2.5779 of 5 stars		$23.45
-3.5%		$43.14
+84.0%		N/A$1.05B$45.95MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ELYM) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel